<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00810121</url>
  </required_header>
  <id_info>
    <org_study_id>KETOP_L_03948</org_study_id>
    <secondary_id>2008-003375-41</secondary_id>
    <nct_id>NCT00810121</nct_id>
  </id_info>
  <brief_title>Study of Non Inferiority Bi-Profenid速 200mg Versus Bi-Profenid速 300mg Among Patients Presenting of the Post-traumatic or Rheumatologic Acute Affections of the Locomotor Apparatus (BIPROPAIN)</brief_title>
  <official_title>Non-inferiority Study of Bi-Profenid速 200 mg Versus Bi-Profenid速 300 mg in Patients Presenting With Pain Related to Closed, Benign, Acute Post-traumatic Conditions of the Motor System or Acute, Non-infectious Rheumatologic Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      To demonstrate the non-inferiority of Bi-Profenid 100 mg x 2 day versus Bi-Profenid 150 mg x&#xD;
      2 day in patients presenting with pain related to closed, benign, acute post-traumatic&#xD;
      conditions of the motor system or acute, non-infectious rheumatologic conditions, by&#xD;
      comparing, on the one hand, changes in resting pain intensity over the entire day, measured&#xD;
      at the end of the day using a numeric scale (NS), over 5 days and, on the other hand, total&#xD;
      intake over 5 days of concomitant analgesics.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To describe concomitant analgesic treatments&#xD;
&#xD;
        -  To describe the time between baseline and use of a step I, II or III analgesic&#xD;
&#xD;
        -  To evaluate patients pain relief using a Likert 4-class scale (complete or substantial&#xD;
           relief, moderate relief slight relief and absence of relief) at D5&#xD;
&#xD;
        -  To evaluate changes in intensity of pain when moving, over the entire day, measured at&#xD;
           the end of the day using a numeric scale, over 5 days&#xD;
&#xD;
        -  To evaluate the patients overall satisfaction at the end of treatment using a 4-point&#xD;
           Simple Verbal Scale (SVS) (very satisfied, somewhat satisfied, somewhat unsatisfied,&#xD;
           very unsatisfied)&#xD;
&#xD;
        -  To evaluate the patients overall satisfaction at the end of the study using a 4-point&#xD;
           Simple Verbal Scale (EVS) (very satisfied, somewhat satisfied, somewhat unsatisfied,&#xD;
           very unsatisfied)&#xD;
&#xD;
        -  To compare the safety of the two treatments&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resting pain intensity measured using the numeric scale (NS) at the end of the day, and total intake of concomitant analgesics over 5 days. For these two parameters, the maximum value will be assigned to patients who used step II or III analgesics</measure>
    <time_frame>between D1 and D5, at the end of the day</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">409</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketoprofen 100 mg b.i.d. for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketoprofen 150 mg b.i.d. for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketoprofen 100 mg</intervention_name>
    <description>100 mg b.i.d. for 5 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketoprofen</intervention_name>
    <description>150 mg b.i.d. for 5 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Male or female, more than 18 and less than 65 years of age,&#xD;
&#xD;
          -  Women using a method of contraception and with a negative pregnancy test before&#xD;
             entering the study, or women who have been menopausal for at least 1 year,&#xD;
&#xD;
          -  Patients meeting one of the following criteria:&#xD;
&#xD;
          -  Closed benign trauma of the motor system occurring within the last 24 hours,&#xD;
&#xD;
          -  Contusion of the motor system occurring within the last 24 hours,&#xD;
&#xD;
          -  Acute rheumatologic conditions (acute lower back pain, lumbar sciatica,&#xD;
             cervicobrachial neuralgia),&#xD;
&#xD;
          -  Abarticular rheumatism,&#xD;
&#xD;
          -  Requiring treatment with Bi-Profenid for 5 days,&#xD;
&#xD;
          -  With resting pain intensity measured on a numeric scale at baseline &gt;or= 3 (before&#xD;
             administration of any treatment),&#xD;
&#xD;
          -  Receiving a prior medical examination suited to the study&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  Need for surgery,&#xD;
&#xD;
          -  Need for hospitalization,&#xD;
&#xD;
          -  Need for an analgesic other than step I at the baseline visit,&#xD;
&#xD;
          -  Need for treatment with another selective or non-selective NSAID (per os and/or&#xD;
             topical), including aspirin, selective cyclo-oxygenase 2 inhibitors, corticosteroids&#xD;
             or muscle relaxants at baseline and throughout the study,&#xD;
&#xD;
          -  Serious trauma: knee luxation, any fracture, ruptures such as Achilles tendon rupture,&#xD;
&#xD;
          -  Sprain treated with a cast,&#xD;
&#xD;
          -  Bursitis,&#xD;
&#xD;
          -  Local and/or general severe infection,&#xD;
&#xD;
          -  Pregnant or nursing women,&#xD;
&#xD;
          -  Hypersensitivity to ketoprofen or to any of the excipients of the product,&#xD;
&#xD;
          -  Previous history of asthma triggered by taking ketoprofen or substances with similar&#xD;
             activity such as other NSAIDs or aspirin,&#xD;
&#xD;
          -  Gastrointestinal haemorrhage, cerebrovascular haemorrhage or other active haemorrhage,&#xD;
&#xD;
          -  Previous history of digestive haemorrhage or perforation during previous NSAID&#xD;
             treatment,&#xD;
&#xD;
          -  Active intestinal ulcer,&#xD;
&#xD;
          -  Active peptic ulcer, previous history of peptic ulcer or recurrent haemorrhage (2&#xD;
             separate episodes or more of haemorrhage or ulcerations detected),&#xD;
&#xD;
          -  Severe hepatic failure,&#xD;
&#xD;
          -  Severe renal failure,&#xD;
&#xD;
          -  Severe heart failure,&#xD;
&#xD;
          -  Uncontrolled hypertension,&#xD;
&#xD;
          -  Hypersensitivity or intolerance to gluten, due to the presence of wheat starch&#xD;
             (gluten),&#xD;
&#xD;
          -  Patients treated with oral anticoagulants, heparins, platelet antiaggregants,&#xD;
             selective serotonin reuptake inhibitors (SSRI), lithium, methotrexate, pemetrexed and&#xD;
             immunosuppressants&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Sebille</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>December 16, 2008</study_first_submitted>
  <study_first_submitted_qc>December 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2008</study_first_posted>
  <last_update_submitted>September 24, 2009</last_update_submitted>
  <last_update_submitted_qc>September 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

